• Vycor Medical posted a net loss of $396,796, or $0.01 per share, for year ended Dec. 31, 2025.
• Revenue rose 17% to $1,863,400.
• Operating income was $33,900, versus an operating loss in 2024.
• Vycor Medical division revenue climbed 18% to $1,796,070, with most of growth from international markets.
• NovaVision NeuroEyeCoach study found home-based use delivered meaningful improvements with no significant differences versus clinic-based use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vycor Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-014079), on March 31, 2026, and is solely responsible for the information contained therein.